Ashley E. Ross, MD, PhD
Ashley E. Ross, MD, PhD

Assistant Professor
Departments of Urology, Oncology and Pathology
Johns Hopkins School of Medicine

Cancer Research Building II, Suite 157, Room 152 1550 Orleans Street Baltimore, MD 21287

Appointments: 410-955-6100

Office: (443) 287-7225


Fax: (410)-614-8096


Free Access to abstracts at PubMed


  1.   Tretter T*, Ross AE*, Dordai DI, Desiderio S.  Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk.  J Exp Med.  2003 Dec 15; 198(12):  1863-73.  *Equal contribution first authorship.
  2. Ross AE, Vuica M, Desiderio S.  Overlapping signals for protein degradation and nuclear localization define a role in intrinsic RAG-2 nuclear uptake in dividing cells.  Mol Cell Biol. 2003 Aug;23(15):5308-19.
  3. Jiang H, Ross AE, Desiderio S.  Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins.  J Biol Chem.  2004 Feb 27;279(9):  8478-86.
  4. Jiang H, Chang FC, Ross AE, Lee J, Nakayama K, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell  2005 Jun 10;18(6):  699-709.
  5. Ross AE, Handa S, Lingeman JE, Matlaga BR.  Kidney stones during pregnancy:  an investigation into stone composition.  Urol Res.  2008 May; 36(2):  99-102.
  6. Musicki B, Ross AE, Champion HC, Burnett AL, Bivalacqua TJ.  Posttranslational modification of constitutive nitric oxide synthase in the penis.  J Androl 2009 Jul-Aug; 30(4):  352-62.
  7. Loeb S, Epstein JI, Ross AE, Shultz L, Humphreys EB, Jarow JP.  Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy.  BJU Int 2010 Mar 25.
  8. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Ketterman A, Feng Z, Carter HB, Walsh PC.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.  J Clin Oncol.  2010 Jun 10;28(17):2810-6.
  9. Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL.  Attenuated RhoA/Rho-Kinase signaling in the penis of transgenic sickle cell mice.  Urology. 2010 Aug: 76(2):510.e7-12.
  10. Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M.  A chemical genetic screen for modulators of asymmetrical 2,2’-dimeric naphthoquinone cytotoxicity in yeast.  PLoS ONE 2010, May 26;5(5):e10846.
  11. Cilip CM, Ross AE, Jarow J, Fried NM.  Application of an optical clearing agent during noninvasive laser coagulation of the canine vas deferens.  J Biomed Opt. 2010 Jul-Aug; 15(4):04001.
  12. Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M.  Dimeric napthoquinones, a novel class of compounds with prostate cancer cytotoxicitiy.  BJU Int.  2010 Dec 22.
  13. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C. Fan J, Berman DM, Schaeffer EM.  Gene expression pathways of high grade localized prostate cancer.  Prostate 2011, Feb 25.
  14. Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW.  A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.  J Urol 2011.  May; 185(5):  1691-7.\
  15. Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM.  Molecular effects of genistein on male urethral development.  J. Urol 2011.  May; 185(5):1894-8.
  16. Loeb S, Feng Z, Ross AE, Trock BJ, Humpreys EB, Walsh PC. Can we stop prostate-specific antigen testing 10 years after radical prostatectomy?  J Urol 2011.  Aug; 186(2):  500-5.
  17. Pierorazio PM, Ross AE, Han M, Epstein J, Walsh PC, Partin A, Schaeffer EM.  Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.  BJUI 2011, Aug 22.
  18. Gupta AD, Bandari J, Ross AE, Tufaro AP, Bivalacqua TJ.  Management of primary aquamouns cell carcinoma at the mucocutaneous junction of an illeal conduit.  Urology.  2011, Sept 9.
  19. Cilip CM, Pierorazio PM, Ross AE, Allaf ME, Fried NM.  High-frequency ultrasound imaging of non-invasive laser coagulation of the canine vas deferens.  Lasers Surg Med.  2011 Sep: 43(8):  838-42.
  20. Emadi A, Le A, Harwood CJ, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M.  Metabolic and electrochemical mechanisms of dimeric naphthoquinones in cytotoxicity in breast cancer cells.  Bioorg Med Chem.  2011 Dec 1:  19(23):  7057-62.
  21. Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.  Effects of treatment with 5-Alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.  BJU Int.  2012 Jan 30.
  22. Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.  Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.  BJU Int.  2012 Feb28.]
  23. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM.  Sox9 is required for prostate development and prostate cancer initiation.  Oncotarget 2012 Jul 2.
  24. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM.  Secreted protein, acidic and rich in cystein-like 1 (SPARCL1) is down regulated in aggressive prostate cacner and is prognostic for poor clinical outcome.  Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82. Epub 2012 Aug 27.
  25. Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, Schaeffer EM.  Wnt signaling through beta-catenin is required for prostate lineage specification.  Dev Biol. 2012 Aug 30.
  26. Sundi D, Ross AE, Humphreys E, Han M. Partin AW, Carter HB, Schaeffer EM.  African American men with very low risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy.  Is active surveillance still an option?  JCO 2013 Aug 20(24)2991-7.
  27.   Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ.  Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy:  The Johns Hopkins Hospital 30-year experience.  Prostate 2013 Sept 9.
  28. Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, Pavlovich CP, Allaf ME, Bivalacqua TJ.  Trends in immediate peri-operative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience.  BJU Int 2013 Jul; 112 (1):45-53.
  29. Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ.  Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy.  The Johns Hopkins Hospital 30 year experience.  Prostate. 2013; 73(15)1673-80.
  30. Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE.  Very high risk localized prostate cancer: definition and outcomes.  PCPD 2014. March 17.
  31. Ross AE, Feng FY, Chadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson JS, Triche T, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes J, Schaeffer EM.  A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.  PCPD 2013.  Oct 22.
  32. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer ME.  Pathological examination of radical prostatectomies in men with very-low-risk disease at biopsy reveals distinct zonal distribution of cancer in African American men.  J Urol. 2014.  191(1):60-7.
  33. Levy DA, Ross AE, Elshafei A, Krishnan N, Hatem A, Jones JS.  Definition of biochemical success following whole gland cryoablation.  J Urol 2014. May 9.
  34. Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.  Outcomes of men with an elevated PSA as their sole pre-operative intermediate or high risk feature.  BJU Int 2014.  April 15
  35. Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ.  Identification of men with the highest risk of early disease recurrence after radical prostatectomy.  Prostate 2014.  May 7.
  36.   Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, Ross AE, Schaeffer EM.  Establishment of a new prostate cancer muti-disciplinary clinic:  format and initial experience.  Prostate 2015; 75(2):  191-9.
  37. Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM.  A human prostatic bacterial isolate alters the prostate microenvironment and accelerates prostate cancer progression.  J Pathol.  2015; Feb; 235(3):  478-89.
  38. Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM.  Racial disparities in oncologic outcomes after radical prostatectomy:  long-term follow-up.  Uroloy 2014 84(6);  1434-41.
  39.   Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM.  Reclassification rates are higher among African American men than Caucasians on active surveillance.  Urology.  2015 85(1):  155-60.
  40. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 Primary Prostate Cancers Rev            eals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. Eur Urol. 2015 May 8. pii: S0302-2838(15)00375-9. doi: 10.1016/j.eururo.2015.04.033. [Epub ahead of print] PubMed PMID: 25964175.
  41. Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM.  Utility of Risk Models in Decision Making After Radical Prostatectomy:  Lessons from a Natural History Cohort of Intermediate and High Risk Men. Eur Urol. 2015 Apr 25. pii: S0302-2838(15)00318-8. doi: 10.1016/j.eururo.2015.04.016. [Epub ahead of print] PubMed PMID: 25922274.
  42. Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM. HES6 promotes prostate cancer aggressiveness independently of Notch signalling. J Cell Mol Med. 2015 Apr 12. doi: 10.1111/jcmm.12537. [Epub ahead of print] PubMed PMID: 25864518.
  43. Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 May 19. doi: 10.1038/pcan.2015.22. [Epub ahead of print] PubMed PMID: 25986914.]
  44. Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humpreys EB, Faraj S, Bezerra, Han M, Partin AW, Trock BJ, Schaeffer EM.  Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.  European Urology. Eur Urol 2015 Jun 6 [Epub ahead of print] PubMed PMID:  26058959.

Review Articles

  1. Vuica M, Ross AE, Nichols JH.  Atypical antipsychotic drugs.  AACC Therapeutic Drug Monitoring and Toxicology.  22(3):66-75,2000.
  2. Ross AE, Carter HB.  A review of the AUA Guideline (2013) on Prostate Cancer Detection and New Approaches to Detection of Prostate Cancer.  AUA Update Series 2014.
  3. Ross AE, D'Amico AV, Freedland S.  Molecular Prognostic Tests for Prostate Cancer. UpToDate. 2014.
  4. Ross AE, D'Amico AV, Freedland SJ.  Which, when and why:  Rational use of tissue based molecular tests in prostate cancer.  Prostate Cancer prostatic diseases.  Accepted, In Press.


Book Chapters

  1. Ross AE, Burnett AL.  Anuria and oliguria.  5-Minute Urology Consult, 2nd Ed. 2009.
  2. Ross AE, Burnett AL.  Balanitis and balanoposthitis.  5-Minute Urology Consult, 2nd Ed.  2009.
  3. Ross AE, Bivalacqua TJ.  Bladder Cancer Superficial.  Handbook of Urology.  2012
  4. Ross AE, Bivalacqua TJ.  Invasive Bladder Cancer/Urinary Diversion.  Handbook of Urology.  2012
  5. Ross AE, Stoianovici D, Allaf ME.  MR-Guided Interventions of the Prostate.  Advances in Image Urologic Surgery.  2014.
  6. Ross AE, Rodriguez R.  Development, Molecular Biology and Physiology of the Prostate, Wein:  Campbell-Walsh Urology 11th Ed. In Press 2015

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion